At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 445 enrolled
Drug / intervention
Lebrikizumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients With Moderate to Severe Atopic Dermatitis.
In Brief
A Phase 3 clinical trial evaluating Lebrikizumab and Placebo for Atopic Dermatitis. Completed, enrolled 445 participants across 89 sites in 8 countries.
Detailed Summary
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 52 weeks in duration. The study is designed to confirm the safety and efficacy of lebrikizumab as monotherapy for treatment of moderate-to-severe atopic dermatitis utilizing a 16-week induction treatment period and a 36-week long-term maintenance treatment period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis
CountriesBulgaria, Canada, Germany, Mexico, Singapore, Taiwan, Ukraine, United States
CollaboratorsDermira, Inc.
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartOct 2019
First PostedNov 2019
Primary CompletionJul 2021
Study CompletionApr 2022
TodayJul 2026
First PostedNov 26, 2019
Enrollment StartOct 29, 2019
Primary CompletionJul 12, 2021
Study CompletionApr 28, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.6 years ago
Interventions
Lebrikizumabbiological
Subcutaneous injection
Placeboother
Subcutaneous Injection